KENNETH J. HILLAN

Corporate Board Profile

Tech Score: 0/100

SANGAMO THERAPEUTICS, INC

Filing Date	Source Excerpt
2021-04-02	Kenneth J. Hillan, M.B., Ch.B., age 60, has served as a member of our Board of Directors since September 2020. Since February 2019, Dr. Hillan has served as Head of Therapeutics of 23andMe, Inc., a privately-held consumer genetics and research company. From October 2011 to December 2017, Dr. Hillan was Chief Executive Officer of Achaogen, Inc., a public biopharmaceutical company, where he was President and President of R&D from January 2018 to October 2018 and a member of the Board of Directors from October 2011 to October 2018. In April 2019, Achaogen filed a voluntary petition for relief under Chapter 11 of the U.S. Bankruptcy Code and most of its assets were subsequently sold to a multinational pharmaceutical company. Previously, Dr. Hillan worked at Genentech, Inc. from 1994 to 2011, where he led the medical and scientific strategies for its Immunology, Tissue Growth and Repair, or ITGR, drug portfolio, and held a number of key leadership positions in research and development, including Senior Vice President of Clinical Development, Inflammation; Vice President of ITGR; Vice President of Development Sciences; and Vice President of Research Operations and Pathology. He also served as Genentech’s Senior Vice President and Head of Clinical Development and Product Development Strategy in Asia-Pacific for Roche in Shanghai, China. He also serves on the board of directors of Zymeworks, Inc., a public biotechnology company. Dr. Hillan previously served on the board of directors of Relypsa, Inc. from June 2014 to September 2016, when it was acquired by Galenica AG. Dr. Hillan received his M.B. Ch.B. (Bachelor of Medicine and Surgery) degree from the Faculty of Medicine at the University of Glasgow, United Kingdom. The Nominating and Corporate Governance Committee and the Board believe that Dr. Hillan’s extensive experience and knowledge in the development of therapeutics and in the biotechnology industry provides the Board with valuable insight and contribution to the Company’s development of genomic medicines. The Nominating and Corporate Governance Committee consists of three directors: Dr. Hillan, Dr. Markels and Ms. Parker. Dr. Hillan was appointed to serve on the Nominating and Corporate Governance Committee effective September 30, 2020. Dr. Hillan received total compensation of $371,093 in 2020.
2022-04-01	Kenneth J. Hillan, M.B., Ch.B., age 61, has served as a member of our Board of Directors since September 2020. The Compensation Committee consists of three directors: Dr. Hillan, Mr. Meyers and Dr. Smith. Dr. Hillan was appointed to serve on the Compensation Committee effective June 1, 2021. The following table sets forth certain information regarding the compensation of each non-employee director for service as a member of the Board of Directors during 2021. Dr. Hillan total compensation was $259,520.

Filing Date

Source Excerpt

2021-04-02

Kenneth J. Hillan, M.B., Ch.B., age 60, has served as a member of our Board of Directors since September 2020. Since February 2019, Dr. Hillan has served as Head of Therapeutics of 23andMe, Inc., a privately-held consumer genetics and research company. From October 2011 to December 2017, Dr. Hillan was Chief Executive Officer of Achaogen, Inc., a public biopharmaceutical company, where he was President and President of R&D from January 2018 to October 2018 and a member of the Board of Directors from October 2011 to October 2018. In April 2019, Achaogen filed a voluntary petition for relief under Chapter 11 of the U.S. Bankruptcy Code and most of its assets were subsequently sold to a multinational pharmaceutical company. Previously, Dr. Hillan worked at Genentech, Inc. from 1994 to 2011, where he led the medical and scientific strategies for its Immunology, Tissue Growth and Repair, or ITGR, drug portfolio, and held a number of key leadership positions in research and development, including Senior Vice President of Clinical Development, Inflammation; Vice President of ITGR; Vice President of Development Sciences; and Vice President of Research Operations and Pathology. He also served as Genentech’s Senior Vice President and Head of Clinical Development and Product Development Strategy in Asia-Pacific for Roche in Shanghai, China. He also serves on the board of directors of Zymeworks, Inc., a public biotechnology company. Dr. Hillan previously served on the board of directors of Relypsa, Inc. from June 2014 to September 2016, when it was acquired by Galenica AG. Dr. Hillan received his M.B. Ch.B. (Bachelor of Medicine and Surgery) degree from the Faculty of Medicine at the University of Glasgow, United Kingdom. The Nominating and Corporate Governance Committee and the Board believe that Dr. Hillan’s extensive experience and knowledge in the development of therapeutics and in the biotechnology industry provides the Board with valuable insight and contribution to the Company’s development of genomic medicines. The Nominating and Corporate Governance Committee consists of three directors: Dr. Hillan, Dr. Markels and Ms. Parker. Dr. Hillan was appointed to serve on the Nominating and Corporate Governance Committee effective September 30, 2020. Dr. Hillan received total compensation of $371,093 in 2020.

2022-04-01

Kenneth J. Hillan, M.B., Ch.B., age 61, has served as a member of our Board of Directors since September 2020. The Compensation Committee consists of three directors: Dr. Hillan, Mr. Meyers and Dr. Smith. Dr. Hillan was appointed to serve on the Compensation Committee effective June 1, 2021. The following table sets forth certain information regarding the compensation of each non-employee director for service as a member of the Board of Directors during 2021. Dr. Hillan total compensation was $259,520.

Data sourced from SEC filings. Last updated: 2026-02-03